{
  "$schema": "folio-library-entry/v1",
  "id": "10665-94830",
  "blocks": [
    {
      "id": "library/10665-94830/blocks/prose-sec-front-matter",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Front matter",
      "pageStart": 1,
      "pageEnd": 7,
      "target": "../sections/sec-front-matter.md",
      "narrative": null,
      "content": "WHO guidelines\nWHO guidelines for screening \nand treatment of precancerous \nlesions for cervical cancer \nprevention\nTest\nAsymptomatic \nwomen\nTest +\nTest -\nTreat\nFollow-up\nWHO guidelines\nWHO guidelines for screening \nand treatment of precancerous \nlesions for cervical cancer \nprevention\nWHO Library Cataloguing-in-Publication Data\nWHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention.\n1.Uterine cervical neoplasms – prevention and control. 2.Precancerous conditions – diagnosis. 3.Precancerous conditions – therapy. \n4.Guideline.  I.World Health Organizat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The front matter of the 2013 WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention, with the cover, cataloguing and copyright page (ISBN 978 92 4 154869 4) and the table of contents. The contents also point to online supplemental GRADE evidence tables for women of negative or unknown HIV status and for women with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-000",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Lists of participants",
      "pageStart": 7,
      "pageEnd": 11,
      "target": "../sections/sec-000-lists-of-participants.md",
      "narrative": null,
      "content": "WHO Steering Group\nNathalie Broutet (Lead) \nReproductive Health and Research \nWHO Headquarters\nJean-Marie Dangou \nDisease Prevention and Control \nWHO Regional Office for Africa\nIbtihal Fadhil \nNoncommunicable Diseases \nWHO Regional Office for the Eastern Mediterranean\nGunta Lazdane \nSexual and Reproductive Health \nWHO Regional Office for Europe\nSilvana Luciani \nCancer Prevention and Control \nWHO Regional Office for the Americas /  \nPan American Health Organization (PAHO)\nArvind Mathur \nMaking Pregnancy Safer and Reproductive Health \nWHO Regional Office for South-East Asia\nAmolo Okero \nCounsell",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Lists the people involved in developing the guideline, beginning with the WHO Steering Group drawn from headquarters, regional and country offices. It continues with members of the other guideline groups and external reviewers from ministries, universities, cancer agencies and NGOs around the world. Each entry gives the person's unit or institution and location.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Process for managing declarations and conflicts of interest",
      "pageStart": 11,
      "pageEnd": 12,
      "target": "../sections/sec-001-process-for-managing-declarations-and-conflicts.md",
      "narrative": null,
      "content": "In September 2010, the External Review Group (ERG) met to decide on the update of Comprehensive \ncervical cancer control: a guide to essential practice (C4-GEP), which was originally published \nin 2006. One of the major conclusions was that the chapter on screening and treatment of \nprecancerous lesions for cervical cancer prevention needed to be updated. This group also made \nrecommendations to the World Health Organization (WHO) on the composition of the Guideline \nDevelopment Group (GDG).\nIn 2011, the GDG and the Methods Group (MG) met several times in joint sessions to develop the \nPICO qu",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Recounts how the guideline arose from a 2010 decision to update WHO's 2006 guide to comprehensive cervical cancer control, and how the guideline groups developed PICO questions, outcomes and a modelling approach in 2011–2012. It notes that the guideline covers screening and treatment of precancerous lesions, not HPV vaccination, although the section title refers to managing conflicts of interest.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acknowledgements",
      "pageStart": 12,
      "pageEnd": 13,
      "target": "../sections/sec-002-acknowledgements.md",
      "narrative": null,
      "content": "The World Health Organization (WHO) would like to thank the members of the Guideline \nDevelopment Group and the Methodology Group for their constant availability and hard work. WHO \nis also very grateful to the External Review Group for making possible the development of these \nessential recommendations for screening and treatment of precancerous lesions for cervical cancer \nprevention. The names of the participants in each group are listed on pages v–viii.\nIn addition, we would like to thank the following staff, fellows, and students from McMaster \nUniversity, Hamilton, Canada, who contribute",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Thanks the guideline groups and McMaster University staff and students who worked on the systematic review. It names the main funders, the Flanders International Cooperation Agency, France's Institut National du Cancer and the GAVI Alliance, and the editing firm.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Acronyms and abbreviations",
      "pageStart": 13,
      "pageEnd": 14,
      "target": "../sections/sec-003-acronyms-and-abbreviations.md",
      "narrative": null,
      "content": "atypical squamous cells of undetermined significance\nCIN\t\ncervical intraepithelial neoplasia\nCKC\t\ncold knife conization\nERG\t\nExternal Review Group\nFICA\t\nFlanders International Cooperation Agency\nGAVI Alliance\t\nformerly the Global Alliance for Vaccines and Immunisation\nGDG\t\nGuideline Development Group\nGRADE\t\nGrading of Recommendations, Assessment, Development and Evaluation\nHPV\t\nhuman papillomavirus\nIARC\t\nInternational Agency for Research on Cancer\nINCa\t\nInstitut National du Cancer (France)\nLEEP\t\nloop electrosurgical excision procedure (also LLETZ)\nLLETZ\t\nlarge loop excision of the transformati",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of acronyms and abbreviations used in the guideline, such as CIN, HPV, LEEP, VIA and GRADE.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Executive summary",
      "pageStart": 14,
      "pageEnd": 16,
      "target": "../sections/sec-004-executive-summary.md",
      "narrative": null,
      "content": "Cervical intraepithelial neoplasia (CIN) is a premalignant lesion that may exist at any one of three \nstages: CIN1, CIN2, or CIN3. If left untreated, CIN2 or CIN3 (collectively referred to as CIN2+) \ncan progress to cervical cancer. Instead of screening and diagnosis by the standard sequence \nof cytology, colposcopy, biopsy, and histological confirmation of CIN, an alternative method is to \nuse a ‘screen-and-treat’ approach in which the treatment decision is based on a screening test \nand treatment is provided soon or, ideally, immediately after a positive screening test. Available \nscreening",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that untreated CIN2 or CIN3 lesions can progress to cervical cancer and describes the screen-and-treat approach, in which treatment follows soon after a positive screening test. It names the available screening tests (HPV test, VIA, cytology) and treatments (cryotherapy, LEEP, cold knife conization), and notes the guideline builds on earlier WHO guidance. It ends with research priorities and states that the recommendations apply to all women, with specific ones for women living with HIV.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen-and-treat strategy summary recommendations",
      "pageStart": 16,
      "pageEnd": 19,
      "target": "../sections/sec-005-screen-and-treat-strategy-summary-recommendation.md",
      "narrative": null,
      "content": "1\t\nThe expert panel includes all members of the WHO Steering Group, the Guideline Development Group (GDG), and the \nExternal Review Group (ERG).\nThe expert panel1 recommends against the use of CKC as a treatment in a screen-\nand-treat strategy. Therefore, all screen-and-treat strategies below involve treatment with \ncryotherapy, or LEEP when the patient is not eligible for cryotherapy.\nThe expert panel suggests: \nf\nf Use a strategy of screen with an HPV test and treat, over a strategy of screen with VIA and \ntreat. In resource-constrained settings, where screening with an HPV test is not feasi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Summarizes the expert panel's recommendations on screen-and-treat strategies for cervical precancer, advising against cold knife conization and favouring cryotherapy, or LEEP when cryotherapy is unsuitable, and setting out paired preferences that generally favour an HPV test (alone or followed by VIA) over VIA alone or cytology with colposcopy, while allowing VIA in low-resource settings and existing quality cytology programmes. It also presents a decision-making flowchart that guides programme managers to a strategy based on existing programmes, resources and quality, with details referred to the annexes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Introduction",
      "pageStart": 19,
      "pageEnd": 20,
      "target": "../sections/sec-006-1-introduction.md",
      "narrative": null,
      "content": "Cervical intraepithelial neoplasia (CIN) is a \npremalignant lesion that may exist at any one \nof three stages: CIN1, CIN2, or CIN3.2 If left \nuntreated, CIN2 or CIN3 (collectively referred \nto as CIN2+) can progress to cervical cancer. \nIt is estimated that approximately 1–2% of \nwomen have CIN2+ each year. This rate is \nreported to be higher in women of HIV-positive \nstatus, at 10% (1–5). The standard practice is \nto screen women using cytology (Pap test), \nand when cytology results are positive the \ndiagnosis of CIN is based on subsequent \ncolposcopy, biopsy of suspicious lesions, \nand then",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces WHO guidelines on screening and treatment of precancerous cervical lesions, explaining that CIN2+ can progress to cancer and that cytology-based screening with colposcopy and biopsy is costly and hard to sustain in low- and middle-income countries, which makes a screen-and-treat approach attractive. It describes the components of such programmes, including HPV testing, cytology and VIA used alone or in sequence, and treatment with cryotherapy, LEEP or cold knife conization. It explains that the guideline compares benefits and harms of strategies to support countries with or without existing programmes, relates it to other WHO guidance and the updated C4-GEP, and stresses considering downstream outcomes rather than test accuracy alone.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Target audience",
      "pageStart": 20,
      "pageEnd": 20,
      "target": "../sections/sec-007-target-audience.md",
      "narrative": null,
      "content": "This guideline is intended primarily for \npolicy-makers, managers, programme officers, \nand other professionals in the health sector \nwho have responsibility for choosing strategies \nfor cervical cancer prevention, at country, \nregional and district levels. Individuals working \nin reproductive health care programmes, \nparticularly programmes for the prevention of \nsexually transmitted infections (STIs) including \nHIV/AIDS and for family planning, at the district \nand primary health care levels, should also \nconsult these guidelines to understand how \nrecommendations are developed and why it \ni",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Identifies the guideline's main audience as health policy-makers, managers and programme officers who choose cervical cancer prevention strategies, as well as reproductive health, STI, HIV and family planning staff.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Purpose",
      "pageStart": 20,
      "pageEnd": 22,
      "target": "../sections/sec-008-purpose.md",
      "narrative": null,
      "content": "This guideline provides recommendations \nfor screen-and-treat strategies to prevent \ncervical cancer (Chapter 3). In addition to the \nrecommendations, this document proposes \na decision-making flowchart for choosing the \nbest screen-and-treat strategy for a particular \nsetting at a programme level (Annex 2); and \n– for use once the strategy is chosen – the \nscreen-and-treat flowcharts for all strategies \nare provided, including the flowcharts \nspecifically for women of negative or unknown \nHIV status (Annex 3), and those for women \nof HIV-positive status or of unknown HIV \nstatus in areas with",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out what the guideline contains: screen-and-treat recommendations, a decision flowchart for choosing a strategy, and flowcharts for each strategy by HIV status. It also describes the methods used and points to online GRADE evidence profiles and evidence-to-recommendation tables.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Methods",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-009-2-methods.md",
      "narrative": null,
      "content": "followed the WHO handbook for guideline \ndevelopment (11, 12).",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A fragment stating that development followed the WHO handbook for guideline development.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-010",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guideline groups",
      "pageStart": 22,
      "pageEnd": 22,
      "target": "../sections/sec-010-guideline-groups.md",
      "narrative": null,
      "content": "WHO formed a Guideline Development Group \n(GDG) for the screen-and-treat strategies to \nprevent cervical cancer, chaired by Joanna \nCain. The 17 selected members provided expert \nclinical guidance and support throughout \nthe guideline development process. WHO \nalso selected an External Review Group \n(ERG) comprising 33 professionals, including \nhealth-care providers with experience in \nscreening and treating CIN, pathologists, \nresearchers in cervical cancer prevention \nand treatment, programme directors, health \neducators, epidemiologists, public health \nofficers, nurses and methodologists. A",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the three groups formed to develop the guideline: a 17-member Guideline Development Group, a 33-member External Review Group and a Methods Group from McMaster University.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-011",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Formulating questions and determining outcomes",
      "pageStart": 22,
      "pageEnd": 23,
      "target": "../sections/sec-011-formulating-questions-and-determining-outcomes.md",
      "narrative": null,
      "content": "outcomes\nIn February 2011, the GDG met to discuss \nthe questions and outcomes to address in \nthe chapter on screen-and-treat strategies \nto appear in the updated C4-GEP, in order to \nincorporate new evidence. The GDG identified \n15 potential questions to guide the evidence \nreview for screening options and treatment \nstrategies for cervical pre-cancer. The MG \nsurveyed the GDG anonymously online using \nSurvey Monkey5 to prioritize the questions and \ndetermine which ones are clinically relevant \nor used in practice; 14 out of 17 members \nresponded. Among the 15 questions, the \nGDG identified 7",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains how the Guideline Development Group in 2011 narrowed 15 possible questions to eight through an online survey, dropping comparisons not used in practice. It then describes how outcomes such as cancer, mortality and treatment complications were ranked, with those rated important or higher included in the evidence review.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-012",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Synthesis of the evidence and preparation of evidence profiles",
      "pageStart": 23,
      "pageEnd": 24,
      "target": "../sections/sec-012-synthesis-of-the-evidence-and-preparation-of-evi.md",
      "narrative": null,
      "content": "preparation of evidence profiles\nA screen-and-treat strategy is made up of two \nlinked parts: the screening test(s) followed by \ntreatment of CIN. The best studies to inform \nscreen-and-treat recommendations are \nrandomized controlled trials in which women \nare randomized to receive ‘screen-and-treat \nstrategy A’ or ‘screen-and-treat strategy B’, \nand health outcomes of all of the women are \nmeasured and presented (even those who \nhad false-negative screening results and were \nnever treated). However, few such studies have \nbeen conducted; most studies do not link the \nscreening strategy with",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that, since few randomized trials link screening tests to treatment of cervical intraepithelial neoplasia (CIN) and report outcomes for all screened women, the WHO screen-and-treat recommendations for cervical pre-cancer rest instead on modelling built from reviews of screening test accuracy and of treatment effects. It describes searches of MEDLINE, EMBASE and an updated Cochrane review, inclusion criteria for diagnostic accuracy studies at low risk of bias, and independent screening and data abstraction by methodologists, with quality assessed through QUADAS and data pooled in Stata. A mathematical model then estimated the benefits and harms of each strategy for women who are HIV-positive or of unknown HIV status, with evidence quality graded by the GRADE approach and evidence-to-recommendation tables prepared for each recommendation.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-14"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-013",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Modelling of health outcomes",
      "pageStart": 24,
      "pageEnd": 25,
      "target": "../sections/sec-013-modelling-of-health-outcomes.md",
      "narrative": null,
      "content": "A screening test with the highest diagnostic \naccuracy is not necessarily the test of choice \nin clinical practice. The decision to recommend \na screening test needs to be justified by its \nimpact on downstream patient-important health \noutcomes. Decision analysis is a powerful tool \nfor evaluating a diagnostic or screening test \non the basis of long-term patient-important \noutcomes when only intermediate outcomes \n– such as test sensitivity and specificity – \nare known. When making the decision to \nrecommend a diagnostic or screening test, a \npanel should consider the health outcomes \ndownstr",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that the most accurate test is not necessarily the best choice, so a decision-analysis model was built to estimate downstream health outcomes of true and false screening results. The model calculated these for VIA, HPV testing and cytology, with assumptions set in advance and sensitivity analyses by HIV status and age.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-014",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Development of the recommendations",
      "pageStart": 25,
      "pageEnd": 26,
      "target": "../sections/sec-014-development-of-the-recommendations.md",
      "narrative": null,
      "content": "In early 2012 (26–28 April), the GDG, \nthe ERG and the MG met to discuss the \nrecommendations. One member each from \nthe GDG and the MG chaired the meeting, \nwhich was attended by experts from around \nthe world, representing various public health \nand medical disciplines. To expand the \ngeographical representativeness of the GDG, \nit was decided that the ERG – a large group \nwith members representing many countries \n– would participate in the development of \nthe recommendations during that meeting. \nMembers of the MG presented evidence \nprofiles and evidence-to-recommendation \ntables, which in",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the April 2012 meeting at which the guideline groups reviewed evidence on benefits, harms, values, resources and feasibility to agree the recommendations. It notes qualitative evidence that women may fear screening and find a second visit burdensome. It explains how strong and conditional recommendations were distinguished, noting that many in this guideline are conditional.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-015",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guideline review and approval process",
      "pageStart": 26,
      "pageEnd": 27,
      "target": "../sections/sec-015-guideline-review-and-approval-process.md",
      "narrative": null,
      "content": "The WHO screen-and-treat strategies to prevent \ncervical cancer underwent the following peer \nreview process before and during development:\n The questions formulated for the development \nof the guidelines were circulated among the \nWHO Steering Group, who also discussed \nthem with the GDG. When the GDG and the \nWHO Steering Group had reached agreement \non the questions, these were sent to the ERG.\n The protocol for systematic reviews was \ncirculated among the GDG. This protocol was \nalso discussed during the ERG meeting, which \nwas also attended by the European Guidelines \nDevelopment Group",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes the review process, in which questions, review protocols, evidence and draft recommendations were circulated among the steering, development and external review groups before WHO clearance. It ends with a table explaining what strong and conditional recommendations mean for patients, clinicians and policy-makers.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Interpretation of strong and conditional recommendations",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../tables/table-1.csv",
      "narrative": "draft",
      "content": "The table explains what a strong (“We recommend…”) and a conditional (“We suggest…”) recommendation imply for patients, for clinicians and for policy-makers.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-94830/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 1. Interpretation of strong and conditional recommendations",
      "pageStart": 26,
      "pageEnd": 26,
      "target": "../tables/table-2.csv",
      "narrative": null,
      "content": null,
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-016",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Recommendations",
      "pageStart": 27,
      "pageEnd": 27,
      "target": "../sections/sec-016-3-recommendations.md",
      "narrative": null,
      "content": "To aid decision-making by programme \nmanagers, a decision-making flowchart or \nalgorithm is provided for choosing the best \nscreen-and-treat strategy for a particular setting \nat a programme level (see Annex 2). Once the \nstrategy has been chosen, flowcharts for each \nstrategy can be followed; these are provided in \nAnnex 3 (negative or unknown HIV status) and \nAnnex 4 (HIV-positive status or unknown HIV \nstatus in areas with high endemic HIV infection). \nThe algorithm and the flowcharts are based on \nthe recommendations detailed in this chapter.",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that a decision flowchart helps programme managers choose a screen-and-treat strategy, with strategy-specific flowcharts by HIV status in the annexes.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-017",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Important considerations that apply to all screen-and-treat recommendations",
      "pageStart": 27,
      "pageEnd": 28,
      "target": "../sections/sec-017-important-considerations-that-apply-to-all-scree.md",
      "narrative": null,
      "content": "all screen-and-treat recommendations\nPopulation targeted by the \nrecommendations \nThe recommendations in this guideline apply \nto women 30 years of age (recommended age \nto start screening) and older because of their \nhigher risk of cervical cancer. However, the \nmagnitude of the net benefit will differ among \nage groups and may extend to younger and \nolder women depending on their baseline \nrisk of CIN2+. Priority should be given to \nscreening women aged 30–49 years, rather \nthan maximizing the number of screening tests \nin a woman’s lifetime. Screening even once in a \nlifetime would be benef",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Sets out considerations that apply to all screen-and-treat recommendations: they target women aged 30 and over, with priority for ages 30–49, while women living with HIV should be screened once sexually active after an HIV-positive result, and VIA is suited to women whose transformation zone is visible, usually under 50. Cryotherapy is the first-choice treatment, with LEEP for women ineligible under the C4-GEP criteria, and all screen-positive women should undergo VIA by a trained provider to determine treatment eligibility and exclude large lesions or suspected cancer.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-12"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-018",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen-and-treat recommendations",
      "pageStart": 28,
      "pageEnd": 34,
      "target": "../sections/sec-018-screen-and-treat-recommendations.md",
      "narrative": null,
      "content": "Recommendation 1. The expert panel \nrecommends against the use of CKC as \ntreatment in a screen-and-treat strategy \n(strong recommendation, \n evidence)\nb.\t In the ‘HPV test followed by VIA’ strategy, \nwomen who are HPV-negative are not \ntreated. Women who are HPV-positive all \nundergo VIA, which is used in this case \nas a second screening test to determine \ntreatment. Women who are HPV-positive \nand VIA-positive will all be treated, \nwhile women who are HPV-positive and \nVIA-negative will not be treated.\nScreening intervals and follow-up\nIdeal screening intervals are provided below \nand for al",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents the screen-and-treat recommendations of the WHO guidelines on cervical pre-cancer, beginning with a strong recommendation against cold knife conization (CKC), which brings more major bleeding and premature delivery than cryotherapy or LEEP without a meaningful gain in cancer prevention. It sets screening intervals of three to five years after a negative VIA or cytology result, at least five years after a negative HPV test, within three years for women who are HIV-positive or of unknown status in high-HIV areas, and follow-up one year after treatment. Conditional recommendations favour screening with an HPV test over VIA where resources allow, and over cytology followed by colposcopy, then treating with cryotherapy or LEEP, each backed by remarks and low- or very-low-quality evidence on recurrences, cancers, deaths and overtreatment. The closing part compares an HPV test followed by colposcopy with an HPV test followed by VIA, finding fewer missed CIN2+ cases but possibly more overtreatment with colposcopy, and noting its greater resource demands and acceptability concerns.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-14"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-019",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Research gaps and further considerations",
      "pageStart": 34,
      "pageEnd": 36,
      "target": "../sections/sec-019-4-research-gaps-and-further-considerations.md",
      "narrative": null,
      "content": "The best evidence to assess the effects of a \nscreen-and-treat strategy is from randomized \ncontrolled trials in which women are randomly \nallocated to receive one or another screen-and-\ntreat strategy and then all screened women are \nfollowed and patient-important health outcomes \n– such as CIN recurrence, cervical cancer and \ncomplications of treatment – are measured. \nWe identified few randomized controlled trials \nthat evaluated screen-and-treat strategies \nand patient-important outcomes. In particular, \nthere were very few studies that assessed the \nstrategies that the GDG ranked as clini",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Notes the scarcity of randomized trials comparing screen-and-treat strategies on patient outcomes, especially for test sequences and for women living with HIV. It raises concerns about cytology programmes in weak health systems and discusses other factors such as loss to follow-up. It also mentions possible additional benefits of screening, such as detecting STIs, that studies do not consistently measure.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-020",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Use of the guideline",
      "pageStart": 36,
      "pageEnd": 36,
      "target": "../sections/sec-020-5-use-of-the-guideline.md",
      "narrative": null,
      "content": "",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "empty"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-021",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guideline dissemination",
      "pageStart": 36,
      "pageEnd": 36,
      "target": "../sections/sec-021-guideline-dissemination.md",
      "narrative": null,
      "content": "These guidelines will be available online at the \nWHO Library database and there will be a link \non WHO’s Sexual and Reproductive Health \nweb page and in the WHO Reproductive Health \nLibrary (RHL), an electronic review journal.7 \nThe publication will also be announced in the \nUNDP/UNFPA/UNICEF/WHO/World Bank \nSpecial Programme of Research, Development \nand Research Training in Human Reproduction \n(HRP) WHO Reproductive Health Update,8 \nwhich reaches more than 2000 subscribers \nand numerous organizations with whom we are \nworking. Many of these organizations will also \ncopy the announcement in",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Describes plans to disseminate the guideline online, through WHO reproductive health channels and newsletters and in print to WHO's distribution lists. It mentions regional and country workshops to adapt the recommendations and notes that translations depend on funding.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-022",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guideline evaluation",
      "pageStart": 36,
      "pageEnd": 37,
      "target": "../sections/sec-022-guideline-evaluation.md",
      "narrative": null,
      "content": "The number of downloads from the WHO web \nsites (headquarters and regional) will be used \nas an indicator of interest in these guidelines.\nWe are working with the WHO regional offices \nto monitor requests from countries for technical \nassistance to use these guidelines. For this \npurpose, national stakeholder meetings will \nbe organized in-country, and feedback on \nthe clarity, feasibility, and usefulness of the \nrecommendations will be recorded.\nWe will also monitor, with the regional \noffices, how many countries change their \nrecommendations based on the publication of \nthese new recommendat",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains that downloads, country requests for technical assistance and changes to national recommendations will be used to evaluate the guideline.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-023",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Guideline update",
      "pageStart": 37,
      "pageEnd": 38,
      "target": "../sections/sec-023-guideline-update.md",
      "narrative": null,
      "content": "The GDG will continue to work with WHO \nin an ad hoc manner, so that the research \ngaps identified during the process can be \naddressed. In addition, evidence published \non new screening and treatment methods \nwill be monitored so that updates to these \nrecommendations can be considered promptly. \nWe anticipate that around five years after the \npublication of these recommendations sufficient \nnew evidence will be available to update the \npresent recommendations and potentially add \nnew ones.\n20\nWHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "States that new evidence will be monitored and the recommendations are expected to be updated about five years after publication.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-024",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "References",
      "pageStart": 38,
      "pageEnd": 40,
      "target": "../sections/sec-024-references.md",
      "narrative": null,
      "content": "1.\t Arbyn M et al. Evidence regarding human papillomavirus testing in secondary prevention of \ncervical cancer. Vaccine, 2012, 30 Suppl 5: F88–99.\n2.\t De Vuyst H et al. Prevalence and determinants of human papillomavirus infection and cervical \nlesions in HIV-positive women in Kenya. British Journal of Cancer, 2012, 107(9):1624–1630.\n3.\t Denny L et al. Human papillomavirus infection and cervical disease in human immunodeficiency \nvirus-1-infected women. Obstetrics & Gynecology, 2008, 111(6):1380–1387.\n4.\t Joshi S et al. Screening of cervical neoplasia in HIV-infected women in India. AIDS, 2013",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A list of references for the guideline, citing mainly studies of HPV testing, cervical lesions in women with HIV and a WHO costing tool.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-025",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Declarations of Interest",
      "pageStart": 40,
      "pageEnd": 43,
      "target": "../sections/sec-025-annex-1-declarations-of-interest.md",
      "narrative": null,
      "content": "Out of the 54 experts who participated in this work, 15 declared an interest related to cervical \ncancer. Although not all of these interests are specifically related to cervical cancer screening and \ntreatment, they are nonetheless all disclosed and summarized below.\nMarc Arbyn was invited by the European Research Organisation on Genital Infection and Neoplasia \n(EUROGIN) to speak at its 2011 conference in Lisbon. EUROGIN covered his travel and lodging \nexpenses. EUROGIN is an organization that promotes and develops, at the level of the European \nregion, research, training, screening, prevent",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Discloses the declared interests of 15 of the 54 experts involved, such as conference travel support, research funding and industry links. Examples include support from EUROGIN for a speaker and PATH projects receiving donated vaccines and HPV tests from manufacturers. Each entry describes the nature of the interest in some detail.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-026",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Decision-making flowchart for screen-and-treat strategies",
      "pageStart": 43,
      "pageEnd": 44,
      "target": "../sections/sec-026-annex-2-decision-making-flowchart-for-screen-and.md",
      "narrative": null,
      "content": "treat strategies\nThis decision-making flowchart or algorithm provides a decision tree to use as a quick reference \nwhen choosing a screen-and-treat strategy at the programme level. Programme managers and \ndecision-makers can start at the top and answer the questions accordingly to determine which \nscreen-and-treat option is best in the context where it will be implemented. It highlights choices \nrelated to resources, which can include costs, staff and training. However, programme managers will \nalso need to consider other factors, such as the number of women who are lost to follow-up with a \ns",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a decision-making flowchart to help programme managers choose a screen-and-treat strategy based on available resources, such as costs, staff and training. It notes that other factors, such as loss to follow-up with multi-test strategies, also need to be considered.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-027",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Flowcharts for screen-and-treat strategies (negative or unknown HIV status)",
      "pageStart": 44,
      "pageEnd": 44,
      "target": "../sections/sec-027-annex-3-flowcharts-for-screen-and-treat-strategi.md",
      "narrative": null,
      "content": "(negative or unknown HIV status)\nThe following flowcharts describe the steps for each of the screen-and-treat strategies that are \navailable. The flowcharts do not indicate which strategy is preferred. Refer to the screen-and-treat \nrecommendations provided in Chapter 3 of the guideline for guidance about which strategies are \nrecommended, and to the decision-making flowchart in Annex 2. For detailed information about \nthe specific factors the guideline panel considered when making the recommendations, refer to the \nevidence-to-recommendation tables for each recommendation (Supplemental materi",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the flowcharts for each screen-and-treat strategy for women of negative or unknown HIV status, noting that they do not show which strategy is preferred.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-028",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with an HPV test and treat with cryotherapy or LEEP",
      "pageStart": 44,
      "pageEnd": 45,
      "target": "../sections/sec-028-screen-with-an-hpv-test-and-treat-with-cryothera.md",
      "narrative": null,
      "content": "for cryotherapy\nWhen an HPV test is positive, treatment is provided. With this strategy, visual inspection with acetic \nacid (VIA) is used to determine eligibility for cryotherapy.\nNegative\nDetermine eligibility for cryotherapy and \nrule out cervical cancer using visual \ninspection with acetic acid (VIA)\nRescreen after a \nminimum interval of \n5 years\nPositive\nEligible for \ncryotherapy, treat \nwith cryotherapy\nNot eligible for  \ncryotherapy, treat \nwith LEEP\nSuspicious for \ncancer\nPost-treatment \nfollow-up at 1 year\nRefer to appropriate \ndiagnosis and \ntreatment\nHPV test\nNote: Refer to the scre",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart for screening with an HPV test and treating positives with cryotherapy, or LEEP if ineligible, with rescreening after at least five years for negatives.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-029",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with an HPV test followed by VIA and treat with cryotherapy or LEEP",
      "pageStart": 45,
      "pageEnd": 46,
      "target": "../sections/sec-029-screen-with-an-hpv-test-followed-by-via-and-trea.md",
      "narrative": null,
      "content": "when not eligible for cryotherapy\nWhen an HPV test is positive, then VIA is provided as a second screening test to determine whether \nor not treatment is offered. Treatment is only provided if BOTH the HPV test and VIA are positive.\nNote: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for \nguidance about which strategies are recommended, and for information on the specific factors to \nconsider when deciding on a strategy.\nNegative\nRescreen after a \nminimum interval of \n5 years\nPositive\nEligible for \ncryotherapy, treat \nwith cryotherapy\nNot eligible for  \nc",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart for screening with an HPV test followed by VIA, treating only women positive on both tests, with rescreening intervals for negative results.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-030",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with VIA and treat with cryotherapy or LEEP",
      "pageStart": 46,
      "pageEnd": 47,
      "target": "../sections/sec-030-screen-with-via-and-treat-with-cryotherapy-or-le.md",
      "narrative": null,
      "content": "cryotherapy\nNote: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for \nguidance about which strategies are recommended, and for information on the specific factors to \nconsider when deciding on a strategy.\nEligible for \ncryotherapy, treat \nwith cryotherapy\nNot eligible for  \ncryotherapy, treat \nwith LEEP\nPost-treatment \nfollow-up at 1 year\nVIA\nNegative\nRescreen every  \n3–5 years \nPositive\nSuspicious for \ncancer\nRefer to appropriate \ndiagnosis and \ntreatment",
      "truncated": false,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart for screening with VIA and treating with cryotherapy or LEEP, with rescreening every three to five years.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-031",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with an HPV test followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "pageStart": 47,
      "pageEnd": 48,
      "target": "../sections/sec-031-screen-with-an-hpv-test-followed-by-colposcopy-w.md",
      "narrative": null,
      "content": "treat with cryotherapy, or LEEP when not eligible for cryotherapy\nNote: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for \nguidance about which strategies are recommended, and for information on the specific factors to \nconsider when deciding on a strategy.\n1\t\nWomen with positive colposcopic impression can receive biopsy for histological confirmation or be treated immediately.\nNegative\nRescreen after a \nminimum interval of \n5 years\nEligible for \ncryotherapy, treat \nwith cryotherapy\nNot eligible for  \ncryotherapy, treat \nwith LEEP\nPost-treatment follow-up",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart for screening with an HPV test followed by colposcopy, with or without biopsy, and treatment of CIN2+ lesions with cryotherapy or LEEP.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-032",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with cytology followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "pageStart": 48,
      "pageEnd": 49,
      "target": "../sections/sec-032-screen-with-cytology-followed-by-colposcopy-with.md",
      "narrative": null,
      "content": "treat with cryotherapy, or LEEP when not eligible for cryotherapy\nNote: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for \nguidance about which strategies are recommended, and for information on the specific factors to \nconsider when deciding on a strategy.\n1\t\nWomen with positive colposcopic impression can receive biopsy for histological confirmation or be treated immediately.\nNormal\nRescreen every  \n3–5 years\nEligible for \ncryotherapy, treat \nwith cryotherapy\nNot eligible for  \ncryotherapy, treat \nwith LEEP\nPost-treatment follow-up at \n1 year\nCytology\nAS",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart for screening with cytology followed by colposcopy, with or without biopsy, and treatment with cryotherapy or LEEP.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-033",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Flowcharts for screen-and-treat strategies (HIV-positive status or unknown HIV status in areas with high endemic HIV infection)",
      "pageStart": 49,
      "pageEnd": 49,
      "target": "../sections/sec-033-annex-4-flowcharts-for-screen-and-treat-strategi.md",
      "narrative": null,
      "content": "(HIV-positive status or unknown HIV status in areas \nwith high endemic HIV infection)\nThe following flowcharts describe the steps for each of the screen-and-treat strategies that are available. \nThe flowcharts do not indicate which strategy is preferred. Refer to the screen-and-treat recommendations \nprovided in Chapter 3 of the guideline for guidance about which strategies are recommended, and to the \ndecision-making flowchart in Annex 2. For detailed information about the specific factors the guideline \npanel considered when making the recommendations, refer to the evidence-to-recommendation",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Introduces the flowcharts for women living with HIV or of unknown status in areas of high HIV prevalence, noting that they do not indicate a preferred strategy.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-034",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with an HPV test and treat with cryotherapy or LEEP",
      "pageStart": 49,
      "pageEnd": 50,
      "target": "../sections/sec-034-screen-with-an-hpv-test-and-treat-with-cryothera.md",
      "narrative": null,
      "content": "for cryotherapy\nWhen an HPV test is positive, treatment is provided. With this strategy, visual inspection with acetic \nacid (VIA) is used to determine eligibility for cryotherapy.\nNote: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for \nguidance about which strategies are recommended, and for information on the factors to consider \nwhen deciding on a strategy.\nNegative\nRescreen  \nwithin 3 years\nPositive\nNot eligible for \ncryotherapy,  \ntreat with LEEP\nPost-treatment \nfollow-up at 1 year\nHPV test \n(women of HIV+ status or unknown status in areas with \nhig",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart for screening women living with HIV with an HPV test and treating positives with cryotherapy or LEEP, with rescreening within three years.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-035",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with an HPV test followed by VIA and treat with cryotherapy or LEEP",
      "pageStart": 50,
      "pageEnd": 51,
      "target": "../sections/sec-035-screen-with-an-hpv-test-followed-by-via-and-trea.md",
      "narrative": null,
      "content": "when not eligible for cryotherapy\nWhen an HPV test is positive, then VIA is provided as a second screening test to determine whether \nor not treatment is offered. Treatment is only provided if BOTH the HPV test and VIA are positive.\nNote: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for \nguidance about which strategies are recommended, and for information on the factors to consider \nwhen deciding on a strategy.\nNegative\nRescreen  \nwithin 3 years\nPositive\nEligible for \ncryotherapy, treat \nwith cryotherapy\nNot eligible for  \ncryotherapy, treat \nwith LEEP\nP",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart from WHO's guidelines on screening and treating precancerous cervical lesions for women living with HIV or of unknown status in high HIV areas, showing a strategy of HPV testing followed by VIA, with treatment by cryotherapy or LEEP only if both tests are positive.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-036",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with VIA and treat with cryotherapy or LEEP",
      "pageStart": 51,
      "pageEnd": 52,
      "target": "../sections/sec-036-screen-with-via-and-treat-with-cryotherapy-or-le.md",
      "narrative": null,
      "content": "cryotherapy\nNote: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for \nguidance about which strategies are recommended, and for information on the factors to consider \nwhen deciding on a strategy.\nNegative\nRescreen  \nwithin 3 years\nPositive\nNot eligible for \ncryotherapy,  \ntreat with LEEP\nPost-treatment \nfollow-up at 1 year\nVIA \n(women of HIV+ status or unknown status  \nin areas with high endemic HIV infection)\nSuspicious for \ncancer\nRefer to appropriate \ndiagnosis and \ntreatment\nEligible for  \ncryotherapy, treat with \ncryotherapy\n34\nWHO guidelines for scre",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart for the same group of women showing a VIA screen-and-treat strategy, with rescreening after negative results, cryotherapy or LEEP for positive results, follow-up at one year and referral if cancer is suspected.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-037",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with an HPV test followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "pageStart": 52,
      "pageEnd": 53,
      "target": "../sections/sec-037-screen-with-an-hpv-test-followed-by-colposcopy-w.md",
      "narrative": null,
      "content": "treat with cryotherapy, or LEEP when not eligible for cryotherapy\nNote: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for \nguidance about which strategies are recommended, and for information on the factors to consider \nwhen deciding on a strategy.\nNegative\nRescreen within  \n3 years\nEligible for \ncryotherapy, treat \nwith cryotherapy\nNot eligible for  \ncryotherapy, treat \nwith LEEP\nPost-treatment follow-up  \nat 1 year\nPositive\nColposcopy\nColposcopy \npositive\nRescreen within  \n3 years\nColposcopy \nnegative\nSuspicious for \ncancer\nRefer to \nappropriate \ndiagno",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart for women living with HIV or of unknown status showing HPV testing followed by colposcopy, with or without biopsy, and treatment by cryotherapy or LEEP, plus rescreening and referral steps.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-038",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Screen with cytology followed by colposcopy (with or without biopsy) and treat with cryotherapy or LEEP",
      "pageStart": 53,
      "pageEnd": 54,
      "target": "../sections/sec-038-screen-with-cytology-followed-by-colposcopy-with.md",
      "narrative": null,
      "content": "treat with cryotherapy or LEEP (when not eligible for cryotherapy)\nNote: Refer to the screen-and-treat recommendations provided in Chapter 3 of the guideline for \nguidance about which strategies are recommended, and for information on the factors to consider \nwhen deciding on a strategy.\n1\t\nWomen with positive colposcopic impression can receive biopsy for histological confirmation or be treated immediately.\nNormal\nRescreen within  \n3 years\nEligible for \ncryotherapy, treat \nwith cryotherapy\nNot eligible for  \ncryotherapy, treat \nwith LEEP\nPost-treatment follow-up at \n1 year\nASCUS or greater\nCol",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A flowchart showing screening by cytology followed by colposcopy, with or without biopsy, and treatment by cryotherapy or LEEP for women living with HIV or of unknown status. It sets out rescreening intervals, post-treatment follow-up and referral when cancer is suspected.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-039",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Search strategies for evidence reviews",
      "pageStart": 54,
      "pageEnd": 56,
      "target": "../sections/sec-039-annex-5-search-strategies-for-evidence-reviews.md",
      "narrative": null,
      "content": "Diagnostic test accuracy of HPV (human papillomavirus) \ntesting, VIA (visual inspection with acetic acid),  \nPap testing (cytology), and colposcopy\nVIA compared to other tests: \nSearch in OVID MEDLINE (up to January 2012)\n1 \t\ncervical intraepithelial neoplasia/\n2 \t\nuterine cervical dysplasia/\n3 \t\nuterine cervical neoplasms/\n4 \t\n((precancer* or pre-cancer* or neoplas* or dysplasia or lesion* or premalignan* or malignan* or \ncancer* or carcinoma*) adj3 cervi*).tw.\n5 \t\n(cin or cin2* or cin3* or cin1).tw.\n6 \t\n1 or 2 or 3 or 4 or 5\n7 \t\nAcetic Acid/ or acetic acid.tw.\n8 \t\n(VIA and visual).tw.\n9 \t\n(v",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Gives the literature search strategies used for the evidence reviews on diagnostic accuracy of HPV testing, VIA, cytology and colposcopy, listing MEDLINE search terms for cervical lesions and each test. It covers searches up to January 2012.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-040",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "PRISMA flow diagram for inclusion and exclusion of studies for evidence reviews",
      "pageStart": 56,
      "pageEnd": 57,
      "target": "../sections/sec-040-annex-6-prisma-flow-diagram-for-inclusion-and-ex.md",
      "narrative": null,
      "content": "WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention\nDiagnostic test accuracy of HPV (human papillomavirus) testing, VIA (visual \ninspection with acetic acid), Pap testing (cytology), and colposcopy\nRecords after duplicates removed  \n(total screening tests, n=1221)  \n(total colposcopy, n=1925)\nCochrane \nsystematic review \nof HPV testing \ncompared to \ncytology  \n(not published)  \n(n=9 studies)\nFull-text articles assessed \nfor eligibility  \n(screening tests, n=178) \n(colposcopy, n=219)\nStudies included in the \nmeta-analysis \n(n=31 + 1 duplicate study)",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "A PRISMA flow diagram showing how studies on screening tests and colposcopy were identified through database searches, screened and assessed for eligibility. It shows the numbers included in the meta-analysis, alongside an unpublished Cochrane review of HPV testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/prose-sec-041",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Reference list of all studies included in the evidence reviews",
      "pageStart": 57,
      "pageEnd": 60,
      "target": "../sections/sec-041-annex-7-reference-list-of-all-studies-included-i.md",
      "narrative": null,
      "content": "evidence reviews\nStudies on diagnostic test accuracy\nAgorastos T et al. Human papillomavirus testing for primary screening in women at low risk of developing \ncervical cancer. The Greek experience. Gynecologic Oncology, 2005, 96(3):714–720.\nBelinson J et al. Shanxi Province Cervical Cancer Screening Study: a cross-sectional comparative trial of \nmultiple techniques to detect cervical neoplasia. Gynecologic Oncology, 2001, 83(2):439–444.\nBigras G, De Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral \nload: Results from a Swiss study comparing HPV test",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The reference list of studies included in the evidence reviews for the cervical cancer screening guidelines, citing mainly diagnostic accuracy studies of HPV testing, VIA, cytology and colposcopy from many countries. It ends with the publication's ISBN.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-94830/blocks/figure-img-p060-1",
      "types": [
        "folio-assistant-core:Figure",
        "doco:Figure"
      ],
      "kind": "figure",
      "title": "",
      "pageStart": 60,
      "pageEnd": 60,
      "target": "../images/img-p060-1.webp",
      "narrative": "draft",
      "content": "An ISBN barcode with the number 9 789241 548694 printed beneath it.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    }
  ]
}
